During the corresponding time, Ionis Pharmaceuticals Inc saw a revenue deteriorated by -40.73 % year on year, sequentially revenue grew by 8.88 %. While revenue at the Ionis Pharmaceuticals Inc 's corporate clients
Ionis Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company earns distribution fees from Sobi for medicines, including an agreement to commercialize TRYNGOLZA outside the U.S., Canada, and China beginning in March 2025. The agreement for TEGSEDI in North America was terminated in October 2023, with discontinuation planned for 2024. In December 2024, the company entered into an agreement with Theratechnologies, Inc. to commercialize DAWNZERA and olezarsen in Canada, also managing their ongoing development. The company collaborates with Bicycle Therapeutics, Metagenomi, and Vect-Horus for technology enhancements and licensing related to peptide technology, gene editing, and RNA-targeted therapeutics, respectively. Additionally, it has a cross-licensing alliance with Alnylam Pharmaceuticals, Inc. involving oligonucleotide chemistry and RNA targeting mechanisms for multiple therapeutic programs and targets.
Ionis Pharmaceuticals Unveils Groundbreaking Research Data at ACAAI 2025 Annual Meeting As the biopharmaceutical landscape continues to evolve, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) recently showcased promising advancements at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting held in Orlando, Florida. Among the highlights were significant findings regarding the company’s innovative RNA-targeted therapies aimed at treating various complex health conditions, including hereditary angioedema (HAE) and severe hypertriglyceridemia (sHTG).Ionis presented compelling new data for DAWNZERA (donidalorsen), the only RNA-targeted prophylactic medicine specifically develo...
Pioneering the Future: Ionis Pharmaceuticals’ Strategic Advances and Financial Milestones CARLSBAD, Calif. - In a significant turn of events this past quarter, Ionis Pharmaceuticals Inc. (Nasdaq: IONS) marked a noteworthy inflection point in its history, signaling its fortification in the pharmaceutical landscape with robust financial results and strategic program advancements. The vibrant updates from the third quarter, ending September 30, 2025, encapsulate the transformative trajectory of this biotech company as it strives to fulfill its mission of delivering innovative medicinal solutions to patients worldwide. Financial Performance and Strategic Outcomes Ionis recent financial report showcases a resi...
Ionis Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company earns distribution fees from Sobi for medicines, including an agreement to commercialize TRYNGOLZA outside the U.S., Canada, and China beginning in March 2025. The agreement for TEGSEDI in North America was terminated in October 2023, with discontinuation planned for 2024. In December 2024, the company entered into an agreement with Theratechnologies, Inc. to commercialize DAWNZERA and olezarsen in Canada, also managing their ongoing development. The company collaborates with Bicycle Therapeutics, Metagenomi, and Vect-Horus for technology enhancements and licensing related to peptide technology, gene editing, and RNA-targeted therapeutics, respectively. Additionally, it has a cross-licensing alliance with Alnylam Pharmaceuticals, Inc. involving oligonucleotide chemistry and RNA targeting mechanisms for multiple therapeutic programs and targets.
Sources:
Ionis Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ionis Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ionis Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
27.65 %